The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In fact this case has previously been observed with small molecular inhibitors of RAF kinase, activating kinase signaling pathways in a dose dependent manner (Hatzivassiliou et al., 2010; Poulikakos et al., 2010)”
From Uncoupling Catalytic and Binding Functions in the Cyclic AMP-Dependent Protein Kinase A (2016) · cites this paper as Hatzivassiliou et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Fluorescent proteins from nonbioluminescent Anthozoa species
Matz, M. V., Fradkov, A. F., Labas, Y. A., Savitsky, A. P., Zaraisky, A. G., Markelov, M. L., & Lukyanov, S. A. (1999) · Nature Biotechnology · doi:10.1038/13657 · Cited by 1,838
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
The RAF proteins take centre stage
Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,228
Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
Yun, J., Rago, C., Cheong, I., Pagliarini, R., Angenendt, P., Rajagopalan, H., Schmidt, K., Willson, J. K. V., Markowitz, S., Zhou, S., et al. (2009) · Science · doi:10.1126/science.1174229 · Cited by 914
A dimerization-dependent mechanism drives RAF catalytic activation
Rajakulendran, T., Sahmi, M., Lefrançois, M., Sicheri, F., & Therrien, M. (2009) · Nature · doi:10.1038/nature08314 · Cited by 489
Regulation and Role of Raf-1/B-Raf Heterodimerization
Rushworth, L. K., Hindley, A. D., O'Neill, E., & Kolch, W. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2262-2272.2006 · Cited by 418
Cited by
Items 101–141 of 141
RAS: Striking at the Core of the Oncogenic Circuitry
Gimple, R. C., & Wang, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00965 · Cited by 174
“Furthermore, while BRAF inhibitors are effective in blocking growth of cancer cells driven by the BRAF-V600E mutation, BRAF inhibition paradoxically activates MAPK signaling in KRAS mutant tumors through inducing increased dimerization of BRAF with RAS (138).”
BackgroundTargeting the mitogen-activated protein kinase pathway: physiological feedback and drug response
Pratilas, C. A., & Solit, D. B. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3064 · Cited by 183
Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors
Mulcahy Levy, J. M., Zahedi, S., Griesinger, A. M., Morin, A., Davies, K. D., Aisner, D. L., Kleinschmidt-DeMasters, B., Fitzwalter, B. E., Goodall, M. L., Thorburn, J., et al. (2017) · eLife · doi:10.7554/elife.19671 · Cited by 175
Ishii, N., Harada, N., Joseph, E. W., Ohara, K., Miura, T., Sakamoto, H., Matsuda, Y., Tomii, Y., Tachibana-Kondo, Y., Iikura, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3937 · Cited by 179
Chen, S.-H., Zhang, Y., Van Horn, R. D., Yin, T., Buchanan, S., Yadav, V., Mochalkin, I., Wong, S. S., Yue, Y. G., Huber, L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0896 · Cited by 171
Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy
Talebi, A., Dehairs, J., Rambow, F., Rogiers, A., Nittner, D., Derua, R., Vanderhoydonc, F., Duarte, J. A. G., Bosisio, F., Van den Eynde, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04664-0 · Cited by 155
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
Sun, C., & Bernards, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.010 · Cited by 155
C-Raf Is Required for the Initiation of Lung Cancer by K-RasG12D
Karreth, F. A., Frese, K. K., DeNicola, G. M., Baccarini, M., & Tuveson, D. A. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-10-0044 · Cited by 149
Molecular Pathways and Mechanisms of BRAF in Cancer Therapy
Poulikakos, P. I., Sullivan, R. J., & Yaeger, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2138 · Cited by 145
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
Yen, I., Shanahan, F., Lee, J., Hong, Y. S., Shin, S. J., Moore, A. R., Sudhamsu, J., Chang, M. T., Bae, I., Dela Cruz, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03515-1 · Cited by 138
Self-citationBRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
“The RAF inhibitor paradox Biochemical studies and crystal structure analysis of RAF dimerization and drug binding have provided molecular insights into the ‘RAF inhibitor paradox’ 9,22,28,51–54 , 109 ( Fig.”
Johnson, G. L., Stuhlmiller, T. J., Angus, S. P., Zawistowski, J. S., & Graves, L. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1081 · Cited by 129
Harnessing the predictive power of preclinical models for oncology drug development
Honkala, A., Malhotra, S. V., Kummar, S., & Junttila, M. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00301-6 · Cited by 121
Resistance to MEK inhibitors: should we co-target upstream?
Poulikakos, P. I., & Solit, D. B. (2011) · Science Signaling · doi:10.1126/scisignal.2001948 · Cited by 119
The genetics and biology of KRAS in lung cancer
Westcott, P. M. K., & To, M. D. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.012.10098 · Cited by 116
Development of siRNA Payloads to Target KRAS -Mutant Cancer
Yuan, T. L., Fellmann, C., Lee, C.-S., Ritchie, C. D., Thapar, V., Lee, L. C., Hsu, D. J., Grace, D., Carver, J. O., Zuber, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0900 · Cited by 113
“In comparison, the small molecule BRAF inhibitor PLX4720 did not inhibit the proliferation of KRAS-mutant cells (Figure 4B), as previously reported (2, 3, 26).”
BackgroundResultSynthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers
Sulahian, R., Kwon, J. J., Walsh, K. H., Pailler, E., Bosse, T. L., Thaker, M., Almanza, D., Dempster, J. M., Pan, J., Piccioni, F., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.090 · Cited by 90
BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling
Vin, H., Ojeda, S. S., Ching, G., Leung, M. L., Chitsazzadeh, V., Dwyer, D. W., Adelmann, C. H., Restrepo, M., Richards, K. N., Stewart, L. R., et al. (2013) · eLife · doi:10.7554/elife.00969 · Cited by 84
Connolly, E. C., Saunier, E. F., Quigley, D., Luu, M. T., De Sapio, A., Hann, B., Yingling, J. M., & Akhurst, R. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2941 · Cited by 82
MEK inhibition in non-small cell lung cancer
Stinchcombe, T. E., & Johnson, G. L. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.09.005 · Cited by 69
Roda, J. M., Wang, Y., Sumner, L. A., Phillips, G. S., Marsh, C. B., & Eubank, T. D. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103817 · Cited by 71
Ahronian, L. G., & Corcoran, R. B. (2017) · Genome Medicine · doi:10.1186/s13073-017-0431-3 · Cited by 67
“In BRAF wild-type cells, BRAF inhibitors induce dimerization of RAF proteins, leading to paradoxical activation of the RAF-MEK-ERK cascade [75, 76].”
Background“Pathway drug cocktail”: targeting Ras signaling based on structural pathways
Nussinov, R., Tsai, C.-J., & Mattos, C. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.07.009 · Cited by 62
Tutuka, C. S. A., Andrews, M. C., Mariadason, J. M., Ioannidis, P., Hudson, C., Cebon, J., & Behren, A. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0684-x · Cited by 58
Puig-Butille, J. A., Vinyals, A., Ferreres, J. R., Aguilera, P., Cabré, E., Tell-Martí, G., Marcoval, J., Mateo, F., Palomero, L., Badenas, C., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.01.021 · Cited by 58
“Moreover, PLX4720 stimulated pERK in MeWo cells rather than inhibiting it, as previously described (Hatzivassiliou et al. 2010).”
ResultWada, M., Horinaka, M., Yamazaki, T., Katoh, N., & Sakai, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113217 · Cited by 50
Kholodenko, B. N. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.014 · Cited by 49
“Following reports that inhibitors increase dimerization of numerous kinases (Hatzivassiliou et al., 2010; Heidorn et al., 2010; Koppikar et al., 2012; Macdonald-Obermann et al., 2013; Poulikakos et al., 2010; Wu et al., 2012), we now assume that the inhibitor binding to a monomer facilitates the…”
BackgroundInfluentialLiu, Y. L., Lai, F., Wilmott, J. S., Yan, X. G., Liu, X. Y., Luan, Q., Guo, S. T., Jiang, C. C., Tseng, H.-Y., Scolyer, R. A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2616 · Cited by 40
Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders
Schadt, E. E., Buchanan, S., Brennand, K. J., & Merchant, K. M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00252 · Cited by 39
Koumaki, K., Kontogianni, G., Kosmidou, V., Pahitsa, F., Kritsi, E., Zervou, M., Chatziioannou, A., Souliotis, V. L., Papadodima, O., & Pintzas, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166061 · Cited by 36
An, R., Merrill, D., Avramova, L., Sturgis, J., Tsiper, M., Robinson, J. P., Turek, J., & Nolte, D. D. (2014) · SLAS Discovery · doi:10.1177/1087057113516674 · Cited by 35
Paradoxical activation of c-Src as a drug-resistant mechanism
Higuchi, M., Ishiyama, K., Maruoka, M., Kanamori, R., Takaori-Kondo, A., & Watanabe, N. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108876 · Cited by 31
Xie, J., Liu, J., Zhao, M., Li, X., Wang, Y., Zhao, Y., Cao, H., Ji, M., Chen, M., & Hou, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043418 · Cited by 29
“This will cause the rebound of phosphorylated ERK and the activation of AKT signaling, thereby attenuating their antitumor effects [16] and causing adverse events such as squamous cell carcinoma of the skin [17,20,21].”
BackgroundResponse and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo
Hartsough, E. J., Kugel, C. H., Vido, M. J., Berger, A. C., Purwin, T. J., Goldberg, A., Davies, M. A., Schiewer, M. J., Knudsen, K. E., Bollag, G., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0705 · Cited by 27
“Vemurafenib and PLX4720 have previously been shown to destabilize homodimerization of full-length mutant BRAF (45) and heterodimerization of WT BRAF kinase domain with CRAF (46).”
InfluentialUncoupling Catalytic and Binding Functions in the Cyclic AMP-Dependent Protein Kinase A
Kim, J., Li, G., Walters, M. A., Taylor, S. S., & Veglia, G. (2016) · Structure · doi:10.1016/j.str.2015.11.016 · Cited by 25
Algazi, A. P., Rotow, J., Posch, C., Ortiz‐Urda, S., Pelayo, A., Munster, P. N., & Daud, A. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12777 · Cited by 23
Dynamic Protein Allosteric Regulation and Disease
Nussinov, R., Tsai, C.-J., & Jang, H. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-8719-7_2 · Cited by 18
Pimasertib-associated ophthalmological adverse events
van Dijk, E. H. C., Kruit, W. H. J., Jager, M. J., Luyten, G. P. M., Vingerling, J. R., & Boon, C. J. F. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13677 · Cited by 9
Unveiling the Domain-Specific and RAS Isoform-Specific Details of BRAF Regulation
Trebino, T., Markusic, B., Nan, H., Banerjee, S., & Wang, Z. (2023) · doi:10.1101/2023.04.24.538112 · Cited by 1
Unveiling the Domain-Specific and RAS Isoform-Specific Details of BRAF Regulation
(2023) · doi:10.7554/elife.88836.2 · Cited by 1
Burtscher, M. L., Garrido-Rodriguez, M., Rivera Mejias, P. A., Papagiannidis, D., Becher, I., Selegato, D. M., Potel, C., Jung, F., Zimmermann, M., Saez-Rodriguez, J., et al. (2026) · bioRxiv · doi:10.64898/2026.02.09.704793
Metadata
- Authors
- Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., Morales, T., Aliagas, I., Liu, B., Sideris, S., Hoeflich, K. P., Jaiswal, B. S., Seshagiri, S., Koeppen, H., Belvin, M., Friedman, L. S., & Malek, S.
- Venue
- Nature
- Published
- 2010-02-03
- Volume
- 464
- Issue
- 7287
- Pages
- 431-435
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2051165598
- Cited by
- 1,622
- References
- 29
- FWCI
- 61.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.